Forbes

Legal psychedelic medicine is poised to soon disrupt the multibillion-dollar mental health field. Treatments being trialed today in clinical settings using substances like psilocybin-containing mushrooms will soon offer legal alternatives to the more than 50 percent of patients receiving therapy for major depressive disorder (MDD) who do not respond to approved depression medications.

As psychedelic substances meet with ever-decreasing resistance from the public — evidenced by the growing number of U.S. cities passing decriminalization laws — the reality of adding psychedelic treatments to the mental health landscape is coming sharper into focus.

Read the full article HERE

 

.
Back To All Blog Articles

Ready to learn why organizations like yours are
making the switch to Arize?

Let us know and we’ll send you an $11.00 Starbucks gift card so you can have a coffee
on us as we continue the conversation.